anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Most previous research on the environmental epidemiology of childhood atopic eczema, rhinitis and wheeze is limited in the scope of risk factors studied. Our study adopted a machine learning approach to explore the role of the exposome starting already in the preconception phase.
METHODS: We performed a combined analysis of two multi-ethnic Asian birth cohorts, the Growing Up in Singapore Towards healthy Outcomes (GUSTO) and the Singapore PREconception Study of long Term maternal and child Outcomes (S-PRESTO) cohorts. Interviewer-administered questionnaires were used to collect information on demography, lifestyle and childhood atopic eczema, rhinitis and wheeze development. Data training was performed using XGBoost, genetic algorithm and logistic regression models, and the top variables with the highest importance were identified. Additive explanation values were identified and inputted into a final multiple logistic regression model. Generalised structural equation modelling with maternal and child blood micronutrients, metabolites and cytokines was performed to explain possible mechanisms.
RESULTS: The final study population included 1151 mother-child pairs. Our findings suggest that these childhood diseases are likely programmed in utero by the preconception and pregnancy exposomes through inflammatory pathways. We identified preconception alcohol consumption and maternal depressive symptoms during pregnancy as key modifiable maternal environmental exposures that increased eczema and rhinitis risk. Our mechanistic model suggested that higher maternal blood neopterin and child blood dimethylglycine protected against early childhood wheeze. After birth, early infection was a key driver of atopic eczema and rhinitis development.
CONCLUSION: Preconception and antenatal exposomes can programme atopic eczema, rhinitis and wheeze development in utero. Reducing maternal alcohol consumption during preconception and supporting maternal mental health during pregnancy may prevent atopic eczema and rhinitis by promoting an optimal antenatal environment. Our findings suggest a need to include preconception environmental exposures in future research to counter the earliest precursors of disease development in children.
A processor-implemented system and method is provided for monitoring patient parameters of engagement plans administered to patients. A builder software application on a first processor- based device is provided for creating an engagement plan from an engagement protocol. An engagement software application on the first processor-based device is configured for monitoring the engagement plan to determine that an administering time for administering the engagement plan has been reached. The engagement software application is further configured for generating a notification message when it is determined that the administering time has been reached. The notification message is transmitted to a registered second processor-based device. The notification message includes an interactive software component for receiving a response message from the second processor-based device. The engagement software application is configured to receive the response message and a status, and to determine patient parameters, thereby engaging patients corresponding to the administered engagement plan.
Days 1 through 7, each subject received a placebo run-in. Days 8 through 21, 2 sprays (2 × 50 μg) of Nasonex® Nasal Spray per nostril once daily for 14 days, Total Daily Dose = 4 × 50 μg = 200 μg.
Eligible subjects will receive nemiralisib ELLIPTA 50 µg dry powder (blended with lactose and magnesium stearate) for oral inhalation once daily in the morning for 12 weeks. Albuterol (Salbutamol) MDI or nebules will also be provided to all subjects for use as rescue medication as needed.
Normal dose and interval of Dupixent i.e. 300 mg s.c. every 2 weeks but for subjects who have crossed over after 24 weeks due to unmet effect criteria.
NEW MATERIAL:A colony stimulating factor, which is a homodimer, consisting of two same subunits having an amino acid sequence expressed by then formula and having a colony formation stimulating action on mammalian monocytic-macrophage based cells and the following properties. Molecular weight measured by a sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) method; 70,000-90,000 daltons and 35,000-45,000 daltons for subunits treated with a reducing agent. Isoelectric point (pI); 3.1-3.7. Containing saccharide chains, having alpha-helical structure without losing biological activity even by heating at 60+ or -0.5 deg.C for 60min. USE:A remedy for leukopenia, immunodeficiency, bone marrow transplantation, etc. PREPARATION:Human urine is adjusted to pH 8-9 and insoluble substances are precipitated and separated. The resultant urine is concentrated and adjusted to pH 6.5-7.5, heat-treated at 60 deg.C and adsorbed on an anion exchanger. The adsorbed substance is then eluted and subjected to gel filtration to recover a fraction having >=70,000 molecular weight, which is subsequently adsorbed on a hydrophobic compatible substance, eluted and subjected to high-speed liquid chromatography to afford the aimed substance having subunits expressed by the formula.
Multimorbidity refers to the presence of two or more chronic diseases and is associated with adverse outcomes for patients. Factors such as an ageing population have contributed to a rise in prevalence of multimorbidity globally; however, multimorbidity is often neglected in clinical guidelines. This is largely because patients with multimorbidity are systematically excluded from clinical trials. Accordingly, there is an urgent need to develop novel biomarkers and methods of prognostication for this cohort of patients. The hallmarks of ageing are now thought to potentiate the pathogenesis of multimorbidity. MicroRNAs are small, regulatory, noncoding RNAs which have been implicated in the pathogenesis and prognostication of numerous chronic diseases; there is a substantial body of evidence now implicating microRNA dysregulation with the different hallmarks of ageing in the aetiology of chronic diseases. This article proposes using the hallmarks of ageing as a framework to develop a panel of microRNAs to assess the prognostic burden of multimorbidity. This putative molecular morbidity score would have many potential applications, including assessing the efficacy of clinical interventions, informing clinical decision making and facilitating wider inclusion of patients with multimorbidity in clinical trials.
BACKGROUND: The number of cancer survivors has been increasing in recent years due to advancements in early diagnosis and prolonged survival. Existing literature suggests a connection between cutaneous melanoma (CM) and hematologic malignancies (HM).
AIM: This study aims to examine epidemiological research on the link between CM and HM and explore genetic, biological, and environmental factors contributing to this association.
METHODOLOGY: A literature review and meta-analysis were performed to evaluate the risk of CM following HM and vice versa. Data from included studies, which reported standardized incidence ratios (SIR) or hazard ratios (HR) with 95 % confidence intervals (CI), were pooled using a random effects model. Heterogeneity among studies was assessed using I² and Cochrane Q test statistics. The incidence data were pooled using a random effects model. This review is registered on PROSPERO (CRD42022359887).
RESULTS: Ten studies focused on HM diagnosis in CM patients, comprising a combined cohort of 189,094 individuals and 11 focused on CM diagnosis in HM patients in a cohort of 306,967 individuals. The SIR for HM after CM ranged from 1.25 to 3.12, while the SIR for CM after HM ranged from 0.83 to 4.12. The pooled proportion of HM in CM patients was 62.4 %, and the proportion of CM in HM patients was 19.6 %. Statistical heterogeneity was high, with I² values of 99.19 % and 89.15 %, respectively.
CONCLUSION: This review confirms an association between CM and HM within the same patient. The link is primarily attributed to genetic factors involving BRAF-V600K, tyrosine kinase pathway genes, CDKN2A (P16), and BCL-2. Additionally, risk factors such as ultraviolet radiation and compromised immune function are associated with the incidence of these cancers.
Subjects are 8 years or older with a diagnosis of cerebral palsy and clinical imaging demonstrating isolated periventricular white matter injury. Clinical assessment states that neurologic symptoms are attributed to this isolated injury. Subjects in this group must be able to lie still in a scanner for 1.5 hours in at most 2 sessions and be able to have an MRI. Participants must be able to affirmatively consent or assent with LAR consent.
The invention discloses an application of LASP1 protein in preparing a medicament for treating spinal cord injury repair. According to the invention, experiments such as immunoblotting and immunofluorescence are performed first, and the expression of LASP1 protein in neurons in the acute phase of spinal cord injury is found to be significantly up-regulated. LASP1 protein localizes within the neuronal axons at the formation of axon collaterals and recruits spastin to the formation of axon collaterals to promote further growth of axon collaterals. Further, through an experiment of co-immunoprecipitation, the interaction of LASP1 and spastin is found to form a protein complex. Furthermore, overexpression of LASP1 in neurons significantly promotes the formation of neurite outgrowth in neurons, which requires the involvement of spastin. The invention has the main effects of promoting the microtubule cutting at the formation position of the axon side branch of the neuron after the spinal cord injury, promoting the further growth of the axon side branch to repair the spinal cord injury, and providing a practical scientific basis for clinically treating the spinal cord injury.
The invention discloses a construction method of a scene interactive AI rehabilitation evaluation training and health monitoring system. The system comprises a posture estimation unit, a posture training unit, a rehabilitation planning unit, a real-time fall detection unit and a scene interaction type based on virtual reality. The subject obtains personalized rehabilitation training guidance through a mode of combining gesture intelligent evaluation and doctor remote evaluation. And finishing rehabilitation training of the patient by using the posture training unit. In the evaluation and training process, human body posture data come from video streams captured by cameras, and original video stream signals are output 18 key node data through a posture estimation algorithm of an embedded computing platform and are transmitted to an upper computer through Socket communication. The upper computer runs the Unity virtual engine, binds the human body model according to the received gesture data, and realizes interactive rehabilitation training.
The present invention relates to a temperature-sensitive phosphazene based polymer containing a degradation-controllable ionic group, a use thereof, and a use thereof as a bioactive substance transfer material. The phosphazene based polymer of the present invention has a temperature sensitivity with a sol-gel change by the temperature change, and forms gel when the polymer is injected into the body by the body temperature for easily controlling the discharging of bioactive substances including drugs. The phosphazene based polymer has a functional group which is capable of chemically bonding including an ionic bond, a covalent bond, and a coordinate bond, and has excellent carrying power of the drugs. The degradation speed of the polymer can be controlled by the type of an ionic group for selectively controlling the discharging time by the properties of the drugs. The phosphazene based polymer has excellent biocompatibility to be used as a bioactive substance transfer material. [Reference numerals] (AA) Solution state(room temperature); (BB) Temperature is increased; (CC) Gel state(body temperature)
Group will be subdivided into three subgroups according to their body mass index to normal, over weight and obese type1. All subjects will receive advices for postural correction. .
After the indication for sleeve gastrectomy has been retained by the multidisciplinary committee eligible patients will be contacted and offered to participate in the BARIAXYTOCINE study. At the time of the first outpatient visit (V1), body densitometry and blood sample for estradiol, leptin and oxytocin will be done. Patients will undergo surgery within one month and 6 months after surgery they will undergo the same work-up (V2).
<P>PROBLEM TO BE SOLVED: To develop a coating film for a medical device and to develop an implantable medical device.  <P>SOLUTION: The implantable medical device is coated with any number of biocompatible materials to minimize or substantially eliminate a biological organism's reaction to the introduction of the medical device to the organism. A vascular filter for implantation into the organism comprises a substantially tubular body formed of a plurality of longitudinally arranged first elements and a plurality of second elements connected to the plurality of first elements and to each other. The plurality of second elements form a lattice structure for capturing particulate matter. The vascular filter further comprises a biocompatible vehicle affixed to at least a portion of the substantially tubular body, and at least one agent in therapeutic dosages incorporated into the biocompatible vehicle for the treatment of a disease.  <P>COPYRIGHT: (C)2004,JPO
This Phase 2 randomized, double-blind, placebo-controlled multicenter study consists of 2 treatment periods: a 16-week double-blind, placebo-controlled period (Period 1: Weeks 0 through the end of Week 15) followed by a 36-week open-label period (Period 2: Weeks 16 through 52). Participants are randomized in a 1:1:1 ratio based on Hurley Stage as stratification factor to receive adalimumab 40 mg every week (qwk), adalimumab 40 mg every other week (eow), or matching placebo during Period 1. During Period 2, participants receive open-label adalimumab 40 mg eow with the option to escalate to 40 mg weekly dosing at Week 28 or Week 31 if the participant has a Physician's Global Assessment of moderate disease or worse (score of greater than or equal to 3). The primary objective of the study is to determine the clinical efficacy and safety of participants with moderate to severe chronic hidradenitis suppurativa (HS) after 16 weeks of treatment. The secondary objective is to evaluate the maintenance of efficacy and continued safety of adalimumab for an additional 36 weeks of treatment. (Note: Hurley Stage is a classification system for skin involvement that is largely based on the presence and extent of abscess formation accompanied by scarring and sinus tracts. Hurley Stages are I \[abscess formation without scarring and sinus tracts\], II \[widely separated recurrent abscesses with scarring and sinus tracts\], and III \[multiple interconnected abscesses and sinus tracts across entire area\]. Randomization in this study was performed using stratification by Hurley Stage \[III versus (I or II).) At the present time, Period 1 double-blind data only is provided; additional information will be provided when analysis of open-label Period 2 is completed.
R-loops cause genome instability, disrupting normal cellular functions. Histone acetylation, particularly by p300/CBP-associated factor (PCAF), is essential for maintaining genome stability and regulating cellular processes. Understanding how R-loop formation and resolution are regulated is important because dysregulation of these processes can lead to multiple diseases, including cancer. This study explores the role of PCAF in maintaining genome stability, specifically for R-loop resolution. We found that PCAF depletion promotes the generation of R-loop structures, especially during ongoing transcription, thereby compromising genome stability. Mechanistically, we found that PCAF facilitates histone H4K8 acetylation, leading to recruitment of the a double-strand break repair protein (MRE11) and exonuclease 1 (EXO1) to R-loop sites. These in turn recruit Fanconi anemia (FA) proteins, including FANCM and BLM, to resolve the R-loop structure. Our findings suggest that PCAF, histone acetylation, and FA proteins collaborate to resolve R-loops and ensure genome stability. This study therefore provides novel mechanistic insights into the dynamics of R-loops as well as the role of PCAF in preserving genome stability. These results may help develop therapeutic strategies to target diseases associated with genome instability.
Mild cognitive impairment (MCI) has been frequently interpreted as a transitional phase between healthy cognitive aging and dementia, particularly of the Alzheimer's disease (AD) type. Of note, few studies explored that transition from a multifactorial perspective, taking into consideration the effect of basic factors such as biological sex. In the present study 96 subjects with MCI (37 males and 59 females) were followed-up and divided into two subgroups according to their clinical outcome: "progressive" MCI (pMCI = 41), if they fulfilled the diagnostic criteria for AD at the end of follow-up; and "stable" MCI (sMCI = 55), if they remained with the initial diagnosis. Different markers were combined to characterize sex differences between groups, including magnetoencephalography recordings, cognitive performance, and brain volumes derived from magnetic resonance imaging. Results indicated that the pMCI group exhibited higher low-frequency activity, lower scores in neuropsychological tests and reduced brain volumes than the sMCI group, being these measures significantly correlated. When sex was considered, results revealed that this pattern was mainly due to the influence of the females' sample. Overall, females exhibited lower cognitive scores and reduced brain volumes. More interestingly, females in the pMCI group showed an increased theta activity that correlated with a more abrupt reduction of cognitive and volumetric scores as compared with females in the sMCI group and with males in the pMCI group. These findings suggest that females' brains might be more vulnerable to the effects of AD pathology, since regardless of age, they showed signs of more pronounced deterioration than males.
Eligible patients will be enrolled and planned for Hip Arthroplasty and will be operated with the Echo BiMetric femoral stem and G7 Acetabular cup. This group will receive an E1 liner and a metal head.
A sensor system for obtaining and displaying information relating to physiological parameters, such as Total Hemoglobin and Pulse rate for use by a user such as an athlete. The system can present the measured physiological parameters to the user in a useful way. For example the system can display a visual multi quadrant infographic display, which can present the total hemoglobin values measured by the system in a particular season. The system can also display a visual elevation infographic display, which can present a comparison of the total hemoglobin values measured by the system over a period of time and/or at various altitudes. The system can also display a visual yin-yang infographic display, which can present a comparison of one or more metrics calculated by the system or one or more parameters measured by the system. The system can provide useful information about the user's health and/or well-being and allow the user to quickly and easily view and interpret relevant information.
Prepn. of a compsn. for external application and treatment (in conjunction with UV irradiation) of inflammatory skin diseases comprises (1) incorporating trans-urocaninic acid (I) into a carrier material at an appropriate concn., then (2), either on the body surface or in vitro, irradiating the compsn. with UV light. (I) is thus converted to cis-urocaninic acid (II) which has immunosuppressant activity on cytotoxic lymphocytes. Pref. carrier is an aq. ointment base. Where (II) is formed in vitro, it is subsequently applied to the body surface or admin. systemically. USE - Inhibits the activity of cytotoxic lymphocytes so breaks the pathogenetic mechanisms primarily initiated by such cells. The process is used to treat or prevent, e.g., psoriasis or lichen ruber.
Patients will self-administer NLX-112 2 times each day, once in the morning and once in the evening. Up-titration over 4 weeks, maximal dose of 2 mg/day during 2 weeks, down-titration over 2 weeks.
A compound of formula (I), a pharmaceutically acceptable salt or ester or other derivative thereof:                    
     R 1  is optionally substituted cycloalkyl or optionally substituted saturated heterocyclic group. R 2  is optionally substituted aryl or optionally substituted heteroaryl. A is methylene, carbonyl or sulfonyl. B is a single bond, alkylene or alkenylene. D is oxygen or sulfur. G is alkylene or alkenylene. L is —N(R 3 )— or —C(R 4 )(R 5 )—. R 3  is optionally substituted aryl or optionally substituted heteroaryl. R 4  is H, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted cycloalkyl or optionally substituted saturated heterocyclic group. R 5  is alkyl optionally substituted with amino, amino, optionally substituted acylamino, OH, optionally substituted hydroxyalkyl, alkoxy or —CO—R 6 . R 6  is alkyl, alkoxy or amine residue. R 4  together with R 5  forms a cycloalkane ring, cycloalkene ring, or saturated heterocyclic ring. R 7  is alkyl. Z is two hydrogens or oxygen. n is 0. 1 or 2. These compounds have selective antagonistic activity against the NK 2  receptor.
Background and Objectives: Caesarean scar pregnancy (CSP) is a rare form of ectopic pregnancy in which the early pregnancy implants at the site of the uterine scar. Methotrexate (MTX) in lower doses can be used to treat CSPs. However, MTX administration is associated with a spectrum of side effects that include hematological toxicities. This case report presents a CSP treated with an intragestational injection of MTX and subsequently developed pancytopenia. Materials and Methods: A 23-year-old woman at six weeks and six days of pregnancy was referred as a potential case of CSP. After establishing the diagnosis, she was treated with a transvaginal ultrasound-guided intragestational administration of 80 mg MTX (adjusted to 50 mg/m2 body surface area) under sedation. Results: On day four after the MTX injection, she developed oral ulcers, fever, and pruritic phlyctenular maculopapular rash. Subsequently, the patient developed febrile neutropenia and was admitted to the Intensive Care Unit. On day six, a subsequent exacerbation of the rash was observed with the formation of blisters and purplish spots with concurrent odynophagia and sialorrhea. Ultimately, the patient developed pancytopenia due to bone marrow suppression. Fifteen days after MTX administration, the patient recovered and was discharged from the hospital hemodynamically stable, afebrile, with dropping β-hcg levels, and in good clinical condition. Conclusions: Although methotrexate administration is the preferred option for the treatment of cesarean scar pregnancies, clinicians should be aware of the fact that its use entails potential risks, even when it is used locally. To our knowledge, this case is the first description of pancytopenia due to bone marrow suppression following a single low dose of intragestational methotrexate injection.